559 related articles for article (PubMed ID: 25634360)
1. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
2. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
3. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
[TBL] [Abstract][Full Text] [Related]
4. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
5. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
6. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.
Allan SE; Crome SQ; Crellin NK; Passerini L; Steiner TS; Bacchetta R; Roncarolo MG; Levings MK
Int Immunol; 2007 Apr; 19(4):345-54. PubMed ID: 17329235
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
8. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
[TBL] [Abstract][Full Text] [Related]
9. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
10. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.
Bianchini R; Bistoni O; Alunno A; Petrillo MG; Ronchetti S; Sportoletti P; Bocci EB; Nocentini G; Gerli R; Riccardi C
Eur J Immunol; 2011 Aug; 41(8):2269-78. PubMed ID: 21557210
[TBL] [Abstract][Full Text] [Related]
11. Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood perspective.
Dupont G; Demaret J; Venet F; Malergue F; Malcus C; Poitevin-Later F; Morel J; Monneret G
Cytokine; 2014 Sep; 69(1):146-9. PubMed ID: 24947990
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
[TBL] [Abstract][Full Text] [Related]
14. CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.
Brenu EW; Bartley TJ; Wright CM; Hamilton-Williams EE
Immunol Cell Biol; 2017 Oct; 95(9):803-813. PubMed ID: 28611472
[TBL] [Abstract][Full Text] [Related]
15. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
16. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
[TBL] [Abstract][Full Text] [Related]
17. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E; Howlett J; Porter L; Truman L; Heywood J; Kennet J; Arbon EL; Anselmiova K; Walker NM; Atkar R; Pekalski ML; Rytina E; Evans M; Wicker LS; Todd JA; Mander AP; Bond S; Waldron-Lynch F
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282826
[TBL] [Abstract][Full Text] [Related]
18. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.
Yu A; Snowhite I; Vendrame F; Rosenzwajg M; Klatzmann D; Pugliese A; Malek TR
Diabetes; 2015 Jun; 64(6):2172-83. PubMed ID: 25576057
[TBL] [Abstract][Full Text] [Related]
19. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells.
Shuai X; Wei-min L; Tong YL; Dong N; Sheng ZY; Yao YM
Sci Rep; 2015 Sep; 5():14478. PubMed ID: 26411375
[TBL] [Abstract][Full Text] [Related]
20. Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes.
Aghili B; Amirzargar AA; Rajab A; Rabbani A; Sotoudeh A; Assadiasl S; Larijani B; Massoud A
Iran J Immunol; 2015 Dec; 12(4):240-51. PubMed ID: 26714416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
